Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Currently submitted to: JMIR Preprints

Date Submitted: Nov 28, 2025
Open Peer Review Period: Nov 28, 2025 - Nov 13, 2026
(currently open for review)

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

High-Dose Dexamethasone for the Treatment of Immune Thrombocytopenia: A Randomized Controlled Trial

  • Aliasghar Tabatabaei Mohammadi; 
  • Saeid RazaviDizaji; 
  • Rahim Asghari; 
  • Fatemeh Zahmatyar; 
  • Hanieh Gholami

ABSTRACT

Introduction Immune thrombocytopenic purpura (ITP) is an acquired thrombocytopenia syndrome characterized by platelet destruction due to antiplatelet antibodies. Corticosteroids are the first-line treatment for adult patients with ITP. This study compares the effects of high-dose dexamethasone versus prednisolone in ITP treatment. Materials and Methods This open-label clinical trial involved patients over 18 years diagnosed with ITP (based on ASH criteria) who had not received prior treatment. Participants were randomly assigned (1:1) to receive high-dose dexamethasone (HD-DXM) or prednisolone (PDN). The dexamethasone group received 40 mg intravenously for 4 consecutive days, while the PDN group received 1 mg/kg oral prednisolone for 4 weeks. Daily complete blood counts were obtained to assess treatment response, defined as a platelet count above 30,000/μL. Results A total of 36 patients were evaluated, with 18 in each treatment group. Patients receiving dexamethasone showed significantly reduced hospitalization duration and faster time to reach platelet counts above 30,000/μL (P=0.01 and P=0.002, respectively). Conclusion High-dose dexamethasone significantly decreases the time to initial response and hospitalization duration in ITP patients compared to prednisolone.


 Citation

Please cite as:

Tabatabaei Mohammadi A, RazaviDizaji S, Asghari R, Zahmatyar F, Gholami H

High-Dose Dexamethasone for the Treatment of Immune Thrombocytopenia: A Randomized Controlled Trial

JMIR Preprints. 28/11/2025:88636

DOI: 10.2196/preprints.88636

URL: https://preprints.jmir.org/preprint/88636

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.